A patient-friendly guide to the science, the evidence and the questions worth asking.
At Green Healthcare International, our goal is education before treatment decisions.
Our role is advocate and coordinator. We provide independent education, research insights, patient advocacy and treatment navigation. Green Healthcare International does not conduct research, does not provide medical treatment itself and does not claim that any regenerative therapy cures a condition. If you decide to explore care, we help you ask the right questions, organize your records and compare qualified, appropriately authorized providers.
This Education Center is designed to help patients and families understand regenerative medicine, separate established medicine from emerging research, recognize potential risks and limitations, and know what questions to ask before considering care—whether in Costa Rica, Colombia, Mexico or elsewhere.
We do not believe patients should make important healthcare decisions based solely on advertising, testimonials or promises. Patients should understand the science, the regulatory status of a proposed therapy, the qualifications of the medical professionals involved and the alternatives available to them.
Advanced regenerative medicine is not simply about administering more stem cells. It is about the science, the delivery method, the physician’s expertise, and targeting the appropriate biological pathways.
Closer is not automatically better. Placing cells nearer to an affected area may change where they first go — it does not by itself mean better clinical results. Illustration only.
Standard: IV, systemicInvestigational: intrathecal / neuro-targeted
Standard IV delivery circulates cells throughout the body. Investigational approaches may explore intrathecal delivery or other neurologically targeted methods.
There is no proof that these approaches outperform IV infusion or reverse Parkinson’s disease. Specialist neurological oversight is essential.
Improve my chances vs. baseline? Ask for the studiesStandard: IV, systemicInvestigational: hepatic artery / portal vein catheter
Instead of relying only on systemic IV infusion, researchers have investigated catheter-based delivery through the hepatic artery or the portal venous system.
These routes may change where cells first distribute, but improved liver function or survival has not been consistently demonstrated. Portal access carries significant risks.
Improve my chances vs. baseline? Ask for the studiesStandard: IV, systemicInvestigational: renal-artery catheter
Investigational protocols have examined renal-artery catheter delivery to introduce cells directly into kidney circulation. This may increase initial local exposure compared with IV administration.
Superior kidney recovery has not been established. Vascular injury, embolic complications and contrast-related kidney risks must be considered.
Improve my chances vs. baseline? Ask for the studiesThe same dose and IV approach for many different patients.
Diagnosis, disease severity, lab findings, cell characterization, delivery route, safety and measurable follow-up.
Personalization alone does not establish effectiveness.
Improve my chances vs. baseline? Ask for the studiesWe can never guarantee results. But we can ask the question that matters: would you like to explore whether a targeted, research-driven protocol could improve your chances compared with a standard baseline approach? Ask us for details — we’ll share the published studies and outcome data for your condition so you and your physician can weigh the evidence together.
The question isn’t simply how many cells you’re receiving. It’s who developed the protocol, how the cells are verified, where they’re delivered, and what clinical evidence supports that approach.
For Parkinson’s, liver disease and kidney disease, researchers are exploring targeted delivery methods beyond conventional IV infusion. But closer delivery does not guarantee better results — these techniques remain investigational, and their benefits and risks must be evaluated individually.
What patients should investigate before choosing a clinic
Educational information only. Targeted delivery routes are investigational; they are not established as superior to IV infusion, and outcomes cannot be guaranteed. Green Healthcare International coordinates and advocates — it does not provide treatment. Discuss risks and alternatives with a qualified specialist.
Educational price ranges for Colombia, Mexico and Costa Rica, what separates an advanced physician-led protocol from standard treatment, and an honest evidence level for 18 conditions.
Check my condition →Read in order, or start with the question on your mind.
Understand the scope of regenerative medicine and why the term alone does not establish safety or effectiveness.
Read article 02 / EDUCATIONLearn why cell type, source, processing and the condition being treated all matter.
Read article 03 / EDUCATIONA practical framework for discussing a proposed regenerative or cellular intervention with your clinician.
Read article 04 / EDUCATIONLearn what regulatory status means and why availability is different from evidence of benefit.
Read article 05 / EDUCATIONUnderstand potential complications, uncertainty, financial costs and the risk of delaying established care.
Read article 06 / EDUCATIONAsk about the diagnosis, cell product, evidence, authorization, provider, costs and follow-up before paying.
Read article 07 / EDUCATIONGo beyond testimonials: examine credentials, clinical evidence, product quality, consent and aftercare.
Read article 08 / EDUCATIONUnderstand mesenchymal stromal cells and the variables that distinguish one product or protocol from another.
Read article 09 / EDUCATIONWhat exosomes are, why researchers study them in regeneration and aging, and what to ask before considering one.
Read article 10 / EDUCATIONCompare research types, outcomes, follow-up and relevance to the exact treatment being proposed.
Read article 11 / EMERGING RESEARCHRare stress-enduring stem-like cells discovered in Japan: what small human trials show and why they remain investigational.
Read article 12 / LONGEVITY SCIENCEChronological vs biological age, the 12 hallmarks of aging, and what is actually proven to help.
Read article 13 / TESTING & MEASUREMENTHow DNA-methylation clocks such as TruDiagnostic’s TruAge estimate biological age, why it matters and its limits.
Read articleThe same questions matter wherever care takes place: who will treat you, what you will receive, what evidence supports it, how it is regulated locally, and who will coordinate follow-up.
A treatment offered abroad is not automatically FDA-approved. Local authorization and U.S. authorization are separate questions. Ask for the relevant documentation before making a decision.
Understand regulatory status →Tell us what you want to understand. Choose your condition in our evidence check form and a patient advocate will reply.
Ask an education questionA private, by-application program with a dedicated expert patient advocate, hand-selected physicians and discreet coordination from the first conversation to long-term follow-up.
Click here to explore VIP Healthcare